Abstracts

BISPECIFIC ANTIBODIES PROMOTE NK CELL-MEDIATED ELIMINATION OF THE HIV-1 RESERVOIR

Background: The persistence of long-lived HIV-infected cells comprising the latent reservoir is the main barrier to an effective cure. One strategy for clearing the latent reservoir, known as “shock and kill,” involves selective reactivation of HIV gene expression through treatment with a latency reversing agent (LRA) followed by immune-mediated elimination of HIV-infected cells. To ensure…

IMPACT OF COVID-19 AND HOST FACTORS ON THE HUMORAL IMMUNE REPERTOIRE IN TREATED HIV

Background: People with HIV (PWH) on antiretroviral therapy (ART) appear to be at higher risk for worse COVID-19 outcomes, but the underlying mechanisms–including effects of COVID-19 and host factors on the broader humoral immune repertoire–are poorly understood. Methods: REPRIEVE enrolled a global cohort of ART-treated PWH ages 40-75. COVID+ was defined by positive receptor binding…

NEF FROM PRIMARY HIV INFECTION COUNTERACTS IFITM3 AND RESTORES VIRION INFECTIVITY

Background: Interferon-induced transmembrane protein 3 (IFITM3) is a restriction factor that reduces HIV-1 infectivity by incorporating into virions, inhibiting Env function, and reducing virion entry into cells. We previously found that the accessory protein of murine leukemia virus, glycogag enables viral evasion of IFITM3. However, whether other retroviruses encode the means for IFITM3 counteraction was…

CARD8 INFLAMMASOME MODULATES HIV-1 INFECTION IN CD4+ T CELLS

Background: CARD8 is an innate immune sensor that can be activated through proteolytic cleavage. Recently, we reported that induction of HIV-1 protease activation leads to CARD8 inflammasome-mediated pyroptosis of infected macrophages and CD4+ T cells. However, it remains unclear whether natural HIV-1 infection can activate the CARD8 inflammasome to trigger pyroptosis of CD4+ T cell…

DUAL ANTIRETROVIRAL-LOADED NANOPARTICLES FOR LONG-ACTING SUPPRESSIVE HIV THERAPY

Background: Viral persistence in secondary lymphoid tissues (SLTs) of patients on cART has been linked to low SLT penetration of antiretrovirals (ARVs). Furthermore, suboptimal adherence to ARVs can lead to drug failure and rapid viral rebound from these SLTs. Therapeutic strategies that sustain ARV concentrations in SLTs are essential. Hence, we designed membrane-wrapped poly-lactic acid…

CORONARY ARTERY PLAQUE COMPOSITION AND SEVERITY RELATE TO THE INFLAMMASOME IN HIV

Background: The inflammasome, an innate immune system component that regulates the secretion of powerful proinflammatory cytokines, has increased activity in people with HIV (PWH) despite antiretroviral therapy (ART). However, the relationship between the inflammasome and coronary artery plaque composition and severity is unknown. Methods: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) enrolled…

RETHINKING REMDESIVIR: ENHANCING ANTI-SARS-CoV-2 ACTIVITY OF ORAL LIPID RVn PRODRUGS

Background: SARS-CoV-2 evolution has contributed to successive waves of infections and severely compromised the efficacy of available SARS-CoV-2 monoclonal antibodies. Decaying vaccine-induced immunity, vaccine hesitancy, and limited vaccine protection in older and immunocompromised populations further compromises vaccine efficacy at the population level. Early antiviral treatments, including intravenous remdesivir (RDV), reduce hospitalization and severe disease due…

EFFECT OF NICOTINE RECEPTOR AGONISTS ON INFLAMMATION AND RISK OF CHD AND DEATH IN HIV

Background: People with HIV (PWH) have elevated systemic inflammation, even after HIV viral suppression, which is exacerbated by risky drinking and smoking. Nicotine receptor agonists promote smoking cessation, may reduce alcohol consumption, and may directly reduce inflammation via cholinergic stimulation. If varenicline, cytisine, or nicotine replacement therapy (NRT) differentially reduced biomarkers of inflammation and risk…